
OPKO Health OPK
$ 1.17
0.0%
Quarterly report 2025-Q2
added 07-31-2025
OPKO Health Total Assets 2011-2026 | OPK
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.2 B | 2.01 B | 2.17 B | 2.4 B | 2.47 B | 2.31 B | 2.45 B | 2.58 B | 2.77 B | 2.8 B | 1.27 B | 1.39 B | 290 M | 229 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.8 B | 229 M | 1.95 B |
Quarterly Total Assets OPKO Health
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.97 B | 2.13 B | 2.26 B | 1.98 B | 1.97 B | 2.06 B | 2.16 B | 2.17 B | 2.17 B | 2.22 B | - | 2.31 B | 2.4 B | 2.42 B | 2.42 B | 2.52 B | 2.47 B | 2.47 B | 2.47 B | 2.47 B | 2.31 B | 2.31 B | 2.31 B | 2.31 B | 2.45 B | 2.45 B | 2.45 B | 2.45 B | 2.59 B | 2.59 B | 2.59 B | 2.59 B | 2.77 B | 2.77 B | 2.77 B | 2.77 B | 2.8 B | 2.8 B | 2.8 B | 2.8 B | 1.27 B | 1.27 B | 1.27 B | 1.27 B | 1.39 B | 1.39 B | 1.39 B | 1.39 B | 290 M | 290 M | 290 M | 290 M | 229 M | 229 M | 229 M | 229 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.8 B | 229 M | 1.95 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 19.89 | 10.93 % | $ 211 M | ||
|
Agilent Technologies
A
|
10.7 B | $ 120.39 | 2.46 % | $ 36.6 B | ||
|
Aspira Women's Health
AWH
|
5.46 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | ||
|
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | ||
|
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | ||
|
CareDx, Inc
CDNA
|
413 M | $ 17.63 | 4.75 % | $ 939 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M | ||
|
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | ||
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | ||
|
Co-Diagnostics
CODX
|
24.7 M | $ 1.38 | -4.83 % | $ 1.84 M | ||
|
Exact Sciences Corporation
EXAS
|
5.86 B | - | - | $ 19.8 B | ||
|
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | ||
|
Castle Biosciences
CSTL
|
531 M | $ 24.37 | 3.57 % | $ 677 M | ||
|
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
7.14 B | $ 179.31 | 0.54 % | $ 8.89 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | ||
|
Interpace Biosciences
IDXG
|
33.8 M | $ 2.2 | - | $ 9.73 M | ||
|
Danaher Corporation
DHR
|
83.5 B | $ 198.61 | 1.4 % | $ 142 B | ||
|
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
6.3 B | $ 130.32 | 2.65 % | $ 20.7 B | ||
|
Medpace Holdings
MEDP
|
1.98 B | $ 520.0 | 3.74 % | $ 15 B | ||
|
Fulgent Genetics
FLGT
|
1.22 B | $ 16.02 | 4.71 % | $ 484 M | ||
|
Koninklijke Philips N.V.
PHG
|
26.9 B | $ 29.09 | 1.89 % | $ 20 B | ||
|
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | ||
|
Guardant Health
GH
|
2.01 B | $ 86.4 | 5.1 % | $ 10.8 B | ||
|
QIAGEN N.V.
QGEN
|
6.28 B | - | - | $ 10.6 B | ||
|
Myriad Genetics
MYGN
|
707 M | $ 4.91 | 6.97 % | $ 455 M | ||
|
Anixa Biosciences
ANIX
|
16.1 M | $ 2.88 | 1.05 % | $ 93.5 K | ||
|
Biomerica
BMRA
|
5.94 M | $ 2.1 | 0.96 % | $ 4.82 M | ||
|
Senseonics Holdings
SENS
|
126 M | $ 6.75 | 0.45 % | $ 282 M | ||
|
ICON Public Limited Company
ICLR
|
16.9 B | $ 113.06 | 2.44 % | $ 9.33 B | ||
|
NeoGenomics
NEO
|
1.36 B | $ 8.35 | 4.38 % | $ 1.07 B | ||
|
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 268.87 | 1.78 % | $ 22.4 B | ||
|
Celcuity
CELC
|
467 M | $ 120.85 | 0.37 % | $ 5.65 B | ||
|
Neogen Corporation
NEOG
|
3.44 B | $ 9.61 | 5.14 % | $ 2.08 B | ||
|
Lantheus Holdings
LNTH
|
2.23 B | $ 82.74 | 1.31 % | $ 5.58 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 194.16 | 0.65 % | $ 21.6 B | ||
|
Natera
NTRA
|
1.39 B | $ 214.64 | 6.31 % | $ 21.1 B | ||
|
ENDRA Life Sciences
NDRA
|
3.85 M | $ 4.96 | -4.43 % | $ 3.9 M | ||
|
Invitae Corporation
NVTA
|
1.95 B | - | - | $ 21.2 M | ||
|
National Research Corporation
NRC
|
135 M | $ 17.04 | 1.34 % | $ 381 M | ||
|
Organovo Holdings
ONVO
|
14.6 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
9.86 M | - | -16.95 % | $ 1.54 M |